IE901554L - Polypeptides - Google Patents

Polypeptides

Info

Publication number
IE901554L
IE901554L IE901554A IE155490A IE901554L IE 901554 L IE901554 L IE 901554L IE 901554 A IE901554 A IE 901554A IE 155490 A IE155490 A IE 155490A IE 901554 L IE901554 L IE 901554L
Authority
IE
Ireland
Prior art keywords
terminal
terminal portion
hsa
variant
polypeptide
Prior art date
Application number
IE901554A
Other versions
IE67651B1 (en
Inventor
David James Ballance
Original Assignee
Patrick Anthony Cronin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Anthony Cronin filed Critical Patrick Anthony Cronin
Publication of IE901554L publication Critical patent/IE901554L/en
Publication of IE67651B1 publication Critical patent/IE67651B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof, then the said polypeptide is one of various specified entities, including the 585 to 1578 portion of human fibronectin or a variant thereof. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the 585-1578 portion of human plasma fibronectin. The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host. [GB2246783A]
IE155490A 1989-04-29 1990-04-27 Polypeptides IE67651B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides

Publications (2)

Publication Number Publication Date
IE901554L true IE901554L (en) 1990-10-29
IE67651B1 IE67651B1 (en) 1996-04-17

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
IE155490A IE67651B1 (en) 1989-04-29 1990-04-27 Polypeptides

Country Status (12)

Country Link
EP (1) EP0470165A1 (en)
JP (1) JP2781459B2 (en)
KR (1) KR100227167B1 (en)
AU (1) AU630450B2 (en)
CA (1) CA2015687C (en)
FI (1) FI104255B (en)
GB (2) GB8909916D0 (en)
HU (1) HUT61049A (en)
IE (1) IE67651B1 (en)
IL (1) IL94243A (en)
WO (1) WO1990013653A1 (en)
ZA (1) ZA903237B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
PE99498A1 (en) * 1996-07-26 1999-01-21 Novartis Ag FUSION POLYPEPTIDES
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
KR20010034305A (en) 1998-01-23 2001-04-25 한센 핀 베네드 Process for making desired polypeptides in yeast
JP4087563B2 (en) 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド Erythropoietin analog-human serum albumin fusion
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
TWI315740B (en) 2001-08-15 2009-10-11 Takara Bio Inc
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
DE60335253D1 (en) 2002-03-25 2011-01-20 Takara Bio Inc METHOD OF PRODUCING A CYTOTOXIC LYMPHOCYTE
CN1839202B (en) * 2003-08-22 2012-07-18 宝生物工程株式会社 Process for producing cytotoxic lymphocytes
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
AU2005317828A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
DK2049560T3 (en) 2006-07-13 2013-07-29 Novozymes Biopharma Dk As Process for the preparation of particles of proteinaceous material
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
KR101874834B1 (en) 2009-10-30 2018-07-05 알부메딕스 에이/에스 Albumin variants
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
JP6216921B2 (en) 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
EP3538560A4 (en) * 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
EP3873926A1 (en) * 2018-10-29 2021-09-08 Spin Therapeutics, LLC Compositions and methods for alpha-1-antitrypsin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (en) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
CA2015687A1 (en) 1990-10-29
IE67651B1 (en) 1996-04-17
JP2781459B2 (en) 1998-07-30
WO1990013653A1 (en) 1990-11-15
FI104255B1 (en) 1999-12-15
GB2246783A (en) 1992-02-12
GB2246783B (en) 1992-10-14
FI915073A0 (en) 1991-10-28
EP0470165A1 (en) 1992-02-12
IL94243A0 (en) 1991-01-31
IL94243A (en) 1995-10-31
AU5564690A (en) 1990-11-29
KR100227167B1 (en) 1999-10-15
GB8909916D0 (en) 1989-06-14
JPH04506598A (en) 1992-11-19
FI104255B (en) 1999-12-15
KR920701451A (en) 1992-08-11
CA2015687C (en) 2000-08-29
HUT61049A (en) 1992-11-30
ZA903237B (en) 1991-03-27
HU904413D0 (en) 1992-01-28
AU630450B2 (en) 1992-10-29
GB9119043D0 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
IE901554L (en) Polypeptides
CA2050336A1 (en) Yeast processing system comprising a negatively charged amino acid adjacent to the processing site
AU9156291A (en) Polypeptide analogs of apolipoprotein e, diagnostic systems and methods using the analogs
AU4647889A (en) Insect signal peptide mediated secretion of recombinant proteins
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
CA2089094A1 (en) Expression of recombinant polypeptides with improved purification
EP0089666A3 (en) Human growth hormone variants
AU3498189A (en) Fibronectin binding protein
AU6332399A (en) Member of the tnf ligand family
AU5187190A (en) Improved baculovirus expression system capable of producing foreign gene proteins at high levels
AU4862290A (en) A signal peptide for the secretion of peptides in escherichia coli, a process for obtaining it, and its use
MY127575A (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
KR100295606B1 (en)
EP0249477A3 (en) Functional recombinant analog polypeptides devoid of hydrophobic amino acids
Gluschankof et al. The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12)
WO2001025438A3 (en) Ifn-alpha homologues
EP1033574A3 (en) Morphogenic protein screening method
AU6096090A (en) Mutants of human interleukin-3
EP1006126A3 (en) Osteogenic peptides
EP0333071A3 (en) Polypeptides, methods for their preparation, pharmaceutical compositions comprising them and use
AU7166891A (en) Method of purifying recombinant polypeptides
AU8680691A (en) Intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
AU5407190A (en) Peptides having novel polar n-terminal groups
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU4076189A (en) Recombinant fusion proteins for altering hormone secretion

Legal Events

Date Code Title Description
MK9A Patent expired